Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07038460
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC (NEO-LISI)
Sponsor: Wen-zhao ZHONG
Conditions
Resectable Non-small Cell Lung Cancer
Updated 1 time since 2025 Last updated: Jun 18, 2025 Started: Jul 31, 2025 Primary completion: Dec 31, 2027 Completion: Dec 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Resectable Non-small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by Wen-zhao ZHONG and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Wen-zhao ZHONG
Data source: Guangdong Provincial People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .